Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$224.99
▼ $3.43 (-1.5%)
Market data updated: 09/21 08:16 AM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$32.46B
Day Range
$224.56 - $228.38
52-Week Range
$180.27 - $284.87
Beta
—
Next Earnings
28.10.2026
Support
$190.21
Resistance
$242.40
RMD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-17.7% (1Y)
Strengths: 15/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.43 (3y annualized return 16.1% / max drawdown 37.8%)
Risk
What to watch next
When today echoes the past.
80/100
Similarity
15
Historical Matches
89/100
Analog Quality
-0.7%
Median 40D Outcome
57/100
Pattern Consistency
🟢 Bullish
33%
+6.7% … +14.4%
🟡 Base
27%
+0.2% … +0.6%
🔴 Bearish
40%
-11.6% … -1.3%
Typical timeframe (based on real historical rates clearing a 60% bar): 10 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 33% (95% CI 15%–58%) saw the stock rise within 20 trading days, with a median gain of +0.2%.
Echo #1 — Momentum Breakout
2 occurrence(s) · 50% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 33% (15%–58%) | -0.3% | -4.8% … +3.3% | +0.4% |
| 10D | 20% (7%–45%) | -3.2% | -5.6% … -1.7% | +0.7% |
| 20D | 33% (15%–58%) | +0.2% | -1.4% … +6.5% | +1.5% |
| 40D | 47% (25%–70%) | -0.7% | -8.4% … +5.2% | +2.9% |
| 60D | 33% (15%–58%) | -3.0% | -8.0% … +3.7% | +3.7% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2022-08-16 | 80/100 | ✓ Consolidation | -1.2% | -10.2% |
| 2022-10-20 | 79/100 | Downtrend | +0.7% | +3.9% |
| 2023-01-09 | 79/100 | Downtrend | +7.0% | +5.5% |
| 2022-04-21 | 78/100 | ✓ Consolidation | -17.3% | -6.0% |
| 2023-03-22 | 78/100 | Downtrend | +6.7% | +3.9% |
| 2024-04-11 | 78/100 | Consolidation | +14.4% | +0.4% |
| 2022-01-19 | 77/100 | Downtrend | -1.6% | -3.0% |
| 2022-09-07 | 76/100 | ✓ Consolidation | +0.2% | -0.8% |
| 2022-12-14 | 76/100 | ✓ Consolidation | -1.2% | -5.6% |
| 2024-04-25 | 76/100 | ✓ Consolidation | +15.4% | +14.2% |
| 2022-02-07 | 75/100 | Downtrend | +0.5% | -13.6% |
| 2022-09-29 | 75/100 | Downtrend | +6.3% | -4.6% |
| 2023-02-28 | 74/100 | ✓ Consolidation | +0.0% | +3.5% |
| 2026-03-05 | 73/100 | ✓ Consolidation | -12.2% | -27.0% |
| 2026-04-10 | 72/100 | Downtrend | -9.7% | -10.1% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
65
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
70
$236.59
Now
65
$224.99
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
50
Quality
63
Value
50
Momentum
56
Risk
54
Sentiment
100
Fundamental
83
Institutional
0
Stocks with a similar DNA right now
SCANNING RMD...
Recent media coverage of ResMed highlights its financial and strategic moves, including a **$450 million accelerated share buyback** with Citibank and the **acquisition of MatrixCare by Frazier Healthcare Partners**, which appointed Jonathan Lujan as CEO. Analysts like KeyBanc and Morgan Stanley have maintained **optimistic price targets** ($267 and $225, respectively), praising its **dividend sustainability** (1.25% yield, 22.95% payout ratio) and profitability. The focus remains on **shareholder returns** and **portfolio adjustments** amid market confidence.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about ResMed. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
15
🎯 Conviction (vs. Emotion)
42
Psychology
29
Fundamentals
83
Technical
56
Valuation
50
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+19%
Market Narrative
58
Fundamental Reality
42
Narrative Gap
+16
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
RMD’s psychology is dominated by **euphoria**, despite weak momentum and neutral volume, suggesting traders may be overvaluing recent strength relative to fundamentals (+9% above 200-day average and +2% DCF premium). Overconfidence (2) hints at complacency, as price underperforms EPS growth, while FOMO (3) remains muted. The narrative gap (0) implies no misalignment between sentiment and fundamentals. The key question: *Is the premium justified, or will traders reassess when momentum falters?*
Updated: 09/08/2026, 07:33 PM
What could change this?
👥 What the crowd believes
"KeyBanc raises ResMed price target to $267 from $255"
"$450M accelerated share buyback with Citibank"
"Frazier Healthcare Partners completes acquisition of MatrixCare from ResMed"
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Jack Schwager — 15/100
🗣️ Why do they disagree?
The stark divide in verdicts for RMD reflects a clash between defensive, cyclical, and growth-oriented frameworks. At the top, Walter Bagehot’s near-perfect score suggests the company’s liquidity and resilience would shield it from systemic stress, aligning with his focus on financial stability. Meanwhile, Charles Mackay and Edgar Lawrence Smith’s high scores imply a lack of speculative frenzy and long-term potential, respectively—both favoring a patient, fundamental approach. However, more nuanced investors like Howard Marks and Gerald Loeb temper enthusiasm, noting reasonable risk but no standout edge, while mid-cycle neutralists like Nelson and Veblen see ambiguity in growth sustainability. On the other end, Fisher, Housel, and even the efficient-market camp question whether RMD’s merits justify active selection over passive strategies, with Graham and Lynch outright dismissing it as lacking the margin of safety or growth premium they demand. Schwager’s low score further underscores a consensus among disciplined traders that the setup lacks clear conviction.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 81
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 73
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 71
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 69
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 62
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 60
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 55
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 53
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 52
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 35
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 28
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 15
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 3 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
61.1%
Operating Margin
33.4%
Net Margin
26.9%
EBITDA Margin
36.9%
ROE
23.1%
ROA
17.0%
ROIC
—
EPS
$10.47
Cash
$1.47B
Total Debt
$659.37M
Current Ratio
3.10
Debt/Equity
0.10
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 20.8.2026 | $0.660 |
| 14.5.2026 | $0.600 |
| 13.5.2026 | $0.600 |
| 12.2.2026 | $0.600 |
| 11.2.2026 | $0.600 |
| 13.11.2025 | $0.600 |
| 12.11.2025 | $0.600 |
| 14.8.2025 | $0.600 |
| 13.8.2025 | $0.600 |
| 8.5.2025 | $0.530 |
| 7.5.2025 | $0.530 |
| 13.2.2025 | $0.530 |
How is Fair Value calculated? →
Current Price
$224.99
Estimated Fair Value (DCF)
$217.23
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-3.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.2%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.2% | $1.82B | $1.67B |
| 2 | 8.3% | $1.97B | $1.66B |
| 3 | 6.4% | $2.09B | $1.62B |
| 4 | 4.4% | $2.19B | $1.55B |
| 5 | 2.5% | $2.24B | $1.46B |
Base FCF (last actual year)
$1.65B
Terminal Value
$35.34B
Present Value of Terminal Value
$22.97B
Enterprise Value
$30.92B
Net Debt
$-809.87M
Equity Value
$31.73B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$45.09
Tangible Book Value per Share (Tangible NAV)
$22.07
Sentiment based on basic keywords (not AI) — 13 positive, 4 neutral, 3 negative out of the last 20 articles.
Yahoo · 19.9.2026
SeekingAlpha · 18.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
ChartMill · 15.9.2026
Fintel · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 13.9.2026
MT Newswires · 10.9.2026
MT Newswires · 10.9.2026
SeekingAlpha · 10.9.2026
ResMed (RMD) currently has a StockIQ AI score of 65/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
RMD currently scores 65/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, RMD's estimated fair value is $217.23, which is 3.5% below the current price of $224.99. This is one valuation model among several signals in the fair-value category, not a price target.
RMD's technical score is 56/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Return on equity (ROE): 23.1% — strong; Debt/equity: 0.10.
Based on the real signals StockIQ computed: Calmar: 0.43 (3y annualized return 16.1% / max drawdown 37.8%); Free cash flow growth: -0.7%; Price is below the 200-day average.
Yes — RMD has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Farrell Michael J. | Open Market Sale | 8.9.2026 | 4,991 | -4,991 | $222.44 |
| Farrell Michael J. | Exercise of Derivative Securities | 8.9.2026 | 4,991 | +4,991 | $146.34 |
| Farrell Michael J. | Exercise of Derivative Securities | 8.9.2026 | 4,991 | -4,991 | — |
| FARRELL PETER C | Open Market Sale | 2.9.2026 | 970 | -970 | $234.73 |
| Farrell Michael J. | Exercise of Derivative Securities | 7.8.2026 | 4,991 | -4,991 | — |
| Farrell Michael J. | Exercise of Derivative Securities | 7.8.2026 | 4,991 | +4,991 | $146.34 |
| Farrell Michael J. | Open Market Sale | 7.8.2026 | 4,991 | -4,991 | $205.69 |
| Farrell Michael J. | Exercise of Derivative Securities | 7.8.2026 | 471,247 | +4,991 | $146.34 |
| Farrell Michael J. | Open Market Sale | 7.8.2026 | 466,256 | -4,991 | $205.69 |
| Farrell Michael J. | Exercise of Derivative Securities | 7.8.2026 | 14,975 | -4,991 | — |
| FARRELL PETER C | Open Market Sale | 5.8.2026 | 8,000 | -8,000 | $225.00 |
| FARRELL PETER C | Open Market Sale | 5.8.2026 | 52,773 | -8,000 | $225.00 |
| Farrell Michael J. | Open Market Sale | 7.7.2026 | 4,991 | -4,991 | $218.55 |
| Farrell Michael J. | Exercise of Derivative Securities | 7.7.2026 | 4,991 | -4,991 | — |
| Farrell Michael J. | Exercise of Derivative Securities | 7.7.2026 | 4,991 | +4,991 | $146.34 |
| Farrell Michael J. | Exercise of Derivative Securities | 7.7.2026 | 471,214 | +4,991 | $146.34 |
| Farrell Michael J. | Open Market Sale | 7.7.2026 | 466,223 | -4,991 | $218.55 |
| Farrell Michael J. | Exercise of Derivative Securities | 7.7.2026 | 19,966 | -4,991 | — |
| Farrell Michael J. | Exercise of Derivative Securities | 8.6.2026 | 4,991 | -4,991 | — |
| Farrell Michael J. | Exercise of Derivative Securities | 8.6.2026 | 4,991 | +4,991 | $146.34 |
| Farrell Michael J. | Open Market Sale | 8.6.2026 | 4,991 | -4,991 | $193.96 |
| Farrell Michael J. | Exercise of Derivative Securities | 8.6.2026 | 471,214 | +4,991 | $146.34 |
| Farrell Michael J. | Open Market Sale | 8.6.2026 | 466,256 | -4,991 | $193.96 |
| Farrell Michael J. | Exercise of Derivative Securities | 8.6.2026 | 24,957 | -4,991 | — |
| Rider Michael J | Tax Withholding in Shares | 1.6.2026 | 268.742 | -268.742 | $190.57 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
13,073,165 shares short as of 2026-08-31 · vs. 15,676,616 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
79.8% of trading volume this week was short selling, vs. 79.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology